Matches in SemOpenAlex for { <https://semopenalex.org/work/W2061905057> ?p ?o ?g. }
Showing items 1 to 59 of
59
with 100 items per page.
- W2061905057 endingPage "gahmj.2013.097C" @default.
- W2061905057 startingPage "gahmj.2013.097C" @default.
- W2061905057 abstract "Focus Areas: Integrative Approaches to Care, Pediatrics, Mental HealthBipolar disorder, formerly known as manic-depressive disorder, consists of often recurrent and severe mood episodes. Roughly 1% of children are diagnosed with bipolar disorder; the prevalence doubles in adulthood. The intense mood swings and periods of depression contribute to the significant morbidity and mortality associated with this disorder, which ranks seventh among worldwide causes of nonfatal disease burden. Patients with bipolar disorder commit suicide at a rate that is nearly 25 times that of the general population. The adverse effects—cognitive, functional, substance abuse rates—are exacerbated by co-occurring illnesses. Half of pediatric bipolar disorder patients have an anxiety disorder and thus a worse clinical outcome.With worsened morbidity and higher suicide risk, the treatment of anxiety in patients with bipolar disorder is imperative; however, options are limited, especially in youth. Benzodiazepines have not been efficacious in pediatric anxiety disorder trials and carry the risk of addiction, sedation, and adverse cognitive effects. The mainstays of pharmacological treatment are the selective serotonin reuptake inhibitors (SSRIs). Although generally well-tolerated, long-term medication side effects have not been researched extensively in youth. Also, SSRIs carry a blackbox FDA warning, and many providers are concerned about the risks of switching patients with bipolar disorder into a manic state. In this setting, myo-inositol, a natural structural isomer of glucose, is a promising treatment option that is both naturally derived and generally well tolerated. It has been shown to be useful in the treatment of depression, obsessive compulsive disorder, and panic with similar efficacy to SSRIs. This poster outlines the clinical utility of myo-inositol for the treatment of anxiety in youths with bipolar disorder. Treatment strategies, limitations, and clinical outcomes are discussed both through treatment experiences and a review of the literature. Further avenues for research also are explored." @default.
- W2061905057 created "2016-06-24" @default.
- W2061905057 creator A5013247870 @default.
- W2061905057 creator A5072280036 @default.
- W2061905057 date "2013-01-01" @default.
- W2061905057 modified "2023-10-16" @default.
- W2061905057 title "P03.15. Myo-inositol for Comorbid Anxiety in Children and Adolescents with Bipolar Disorder: Promise and Pitfalls" @default.
- W2061905057 doi "https://doi.org/10.7453/gahmj.2013.097cp.p03.15" @default.
- W2061905057 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3875047" @default.
- W2061905057 hasPublicationYear "2013" @default.
- W2061905057 type Work @default.
- W2061905057 sameAs 2061905057 @default.
- W2061905057 citedByCount "0" @default.
- W2061905057 crossrefType "journal-article" @default.
- W2061905057 hasAuthorship W2061905057A5013247870 @default.
- W2061905057 hasAuthorship W2061905057A5072280036 @default.
- W2061905057 hasBestOaLocation W20619050571 @default.
- W2061905057 hasConcept C118552586 @default.
- W2061905057 hasConcept C126322002 @default.
- W2061905057 hasConcept C15744967 @default.
- W2061905057 hasConcept C170493617 @default.
- W2061905057 hasConcept C2776174506 @default.
- W2061905057 hasConcept C2777427919 @default.
- W2061905057 hasConcept C2778541603 @default.
- W2061905057 hasConcept C558461103 @default.
- W2061905057 hasConcept C70410870 @default.
- W2061905057 hasConcept C71924100 @default.
- W2061905057 hasConceptScore W2061905057C118552586 @default.
- W2061905057 hasConceptScore W2061905057C126322002 @default.
- W2061905057 hasConceptScore W2061905057C15744967 @default.
- W2061905057 hasConceptScore W2061905057C170493617 @default.
- W2061905057 hasConceptScore W2061905057C2776174506 @default.
- W2061905057 hasConceptScore W2061905057C2777427919 @default.
- W2061905057 hasConceptScore W2061905057C2778541603 @default.
- W2061905057 hasConceptScore W2061905057C558461103 @default.
- W2061905057 hasConceptScore W2061905057C70410870 @default.
- W2061905057 hasConceptScore W2061905057C71924100 @default.
- W2061905057 hasIssue "1_suppl" @default.
- W2061905057 hasLocation W20619050571 @default.
- W2061905057 hasLocation W20619050572 @default.
- W2061905057 hasOpenAccess W2061905057 @default.
- W2061905057 hasPrimaryLocation W20619050571 @default.
- W2061905057 hasRelatedWork W1963617120 @default.
- W2061905057 hasRelatedWork W2095545988 @default.
- W2061905057 hasRelatedWork W2105863616 @default.
- W2061905057 hasRelatedWork W2114727704 @default.
- W2061905057 hasRelatedWork W2146174011 @default.
- W2061905057 hasRelatedWork W2149802254 @default.
- W2061905057 hasRelatedWork W2165343866 @default.
- W2061905057 hasRelatedWork W2299212355 @default.
- W2061905057 hasRelatedWork W2342510067 @default.
- W2061905057 hasRelatedWork W2972785439 @default.
- W2061905057 hasVolume "2" @default.
- W2061905057 isParatext "false" @default.
- W2061905057 isRetracted "false" @default.
- W2061905057 magId "2061905057" @default.
- W2061905057 workType "article" @default.